Praluent
PreclinicalSmall molecule
RegeneronPraluent is one of 41 small molecule programs targeting Hyperlipidemia. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Vascular Disease
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Repatha
AmgenApproved
Precose
BayerApproved
Letairis
GileadApproved
Colcrys
Jazz PharmaceuticalsApproved
Xarelto
WWim Janssens
Approved
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Andriol
AAuxilium
Approved
Aricept
EisaiApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment1 trial
Neurocognitive Function1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Praluent. EMBL-EBI & Wellcome Sanger Institute.
- [4]